MedTrace Logo

Study of ASLAN004 in Healthy Subjects

NCT03721263 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2020-08-05

No results posted yet for this study

Summary

This is an open-label, two-part, single-center, first in human (FIH), single ascending dose (SAD) study to assess the effects of single doses of ASLAN004 when administered to healthy subjects. The objective of this study is to evaluate the safety, tolerability, and Pharmacokinetics (PK) of ASLAN004 in healthy subjects.

Conditions

  • Allergic Disorder

Interventions

BIOLOGICAL

ASLAN004

Single Dose

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • ASLAN Pharmaceuticals

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-10-15
Primary Completion
2019-03-27
Completion
2019-06-20

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03721263 on ClinicalTrials.gov